A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full ...

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...

SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Wednesday reported fourth-quarter profit of $124.9 million. The San Rafael, California-based company ...

In the last three months, 8 analysts have published ratings on Biomarin Pharmaceutical BMRN, offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a ...

Ladies and gentlemen, thank you for standing by and welcome to the BioMarin Pharmaceuticals fourth quarter and full year 2024 conference call. All lines have been placed on mute to prevent any ...

BioMarin expects full-year earnings in the range of $4.20 to $4.40 per share, with revenue in the range of $3.1 billion to $3.2 billion. BioMarin shares have decreased slightly since the beginning ...

Citi raised the firm’s price target on BioMarin (BMRN) to $82 from $81 and keeps a Neutral rating on the shares. The company reported a Q4 beat, driven by commercial execution across the ...